Sana Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 328
- Market Cap
- $1.2B
- Website
- http://www.sana.com
- Introduction
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.
Sana Biotechnology Announces Positive Clinical Results in HIP-Engineered Islet Cells Study
Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted into a type 1 diabetes patient evade immune rejection and produce insulin without immunosuppression. C-peptide levels indicate insulin production, and MRI confirms graft survival. The study, conducted with Uppsala University Hospital, marks a significant step towards a scalable, curative treatment for type 1 diabetes.
Sana Biotechnology Announces Positive Clinical Results from First-in-Human Study of HIP-Engineered Islet Cells
Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted into a type 1 diabetes patient evade immune rejection and produce insulin without immunosuppression. Results indicate cell survival, function, and immune evasion, with C-peptide levels confirming insulin production. MRI signals suggest graft survival. The study, conducted with Uppsala University Hospital, marks a significant step towards a scalable, curative treatment for type 1 diabetes without immunosuppression.
Sana Biotechnology Announces Positive Clinical Results
Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted into a type 1 diabetes patient evade immune rejection, produce insulin without immunosuppression, and persist, evidenced by C-peptide levels and MRI signals. This breakthrough suggests a potential scalable, curative treatment for type 1 diabetes.
FDA Activity Recap: December 2024 Features New Approval, a Clinical Hold, and More
In December 2024, the FDA approved Mesoblast’s remestemcel-L for steroid-refractory GvHD, placed a clinical hold on PepGen’s DMD trial, fast-tracked Sana Biotechnology’s SC291 for SLE, and agreed with uniQure on an accelerated approval pathway for Huntington disease gene therapy AMT-130.
Related Clinical Trials:
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc.
Pomerantz LLP investigates Sana Biotechnology, Inc. for potential securities fraud. Sana's stock dropped 9.84% after announcing program suspensions and strategy changes. Investors advised to contact Danielle Peyton for class action information.
Sana Biotechnology Announces Positive Clinical Results for HIP-Engineered Islet Cells in Type 1 Diabetes Treatment
Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted into a type 1 diabetes patient evade immune rejection and produce insulin without immunosuppression. Results include detectable C-peptide levels, indicating insulin production, and MRI evidence of graft survival. The study aims for a scalable, curative treatment for type 1 diabetes.
© Copyright 2025. All Rights Reserved by MedPath